**Name of journal: *World Journal of Diabetes***

**ESPS Manuscript NO: 19192**

**Manuscript Type: Original Article**

***Randomized Clinical Trial***

**Buddy Study: Partners for better health in adolescents with type 2 diabetes**

Sylvetsky AC *et al.* Buddies for adolescents with diabetes

**Allison C Sylvetsky, Radha Nandagopal, Tammy Nguyen, Marisa Abegg, Mahathi Nagarur, Paul Kaplowitz, Kristina I Rother**

**Allison C Sylvetsky, Radha Nandagopal, Tammy Nguyen, Marisa Abegg, Mahathi Nagarur, Kristina I Rother,** Section on Pediatric Diabetes and Metabolism, NIDDK, National Institutes of Health, Bethesda, MD 20892, United States

**Allison C Sylvetsky,** Department of Exercise and Nutrition Sciences, the George Washington University, Washington, DC 20037, United States

**Radha Nandagopal, Paul Kaplowitz,** Division of Endocrinology, Children’s National Medical Center, Washington, DC 20310, United States

**Author contributions:** Nandagopal R, Kaplowitz P and Rother KI designed this research; Nguyen T, Nandagopal R and Abegg M collected the data; Sylvetsky AC, Nagarur M and Rother KI analyzed and interpreted the data; Sylvetsky AC wrote the first draft of the article and all of the authors intellectually contributed to drafting, revising, and writing of the final manuscript; all authors approve of the submission of this manuscript.

**Supported by** The Intramural Research Program of the National Institutes of Health; the National Institute of Diabetes, Digestive; Kidney Diseases in collaboration with the Division of Endocrinology; and Diabetes at the Children’s National Medical Center (Washington, DC). In addition, funding support was provided by the Endocrine Fellows Foundation Marilyn Fishman Grant for Diabetes Research.

**Institutional review board statement:** The study protocol, consents and all study procedures were approved by the Institutional Review Boards at the Children’s National Medical Center and at the NIH Clinical Center.

**Clinical trial registration:** This study is registered at ClinicalTrials.gov. The registration identification number is NCT01007266.

**Informed consent statement:** Informed written consent and assent (in individuals < 18 years of age) were obtained prior to enrollment.

**Conflict-of-interest statement:** None of the authors have any conflicts of interest to report.

**Data sharing statement:** Consent for data sharing was not obtained but the presented data are coded and de-identified and the risk of identification is therefore low. No additional data is available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Kristina I Rother, MD, MHSc,** Section on Pediatric Diabetes and Metabolism, NIDDK, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 8C432A, Bethesda, MD 20892, United States. [kr58q@nih.gov](mailto:kr58q@nih.gov)

**Telephone:** +1-301-4354639

**Fax:** +1-301-4808277

**Received:** April 29, 2015

**Peer-review started:** April 30, 2015

**First decision:** July 10, 2015

**Revised:** July 24, 2015

**Accepted:** September 1, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate whether assigning young, healthy and motivated lay volunteer partners (“buddies”) to adolescents with type 2 diabetes improves hemoglobin A1c (HbA1c).

**METHODS:** Adolescents with type 2 diabetes were randomized to partnering with a “buddy” or to conventional treatment. During the initial screening visit, which coincided with a routine outpatient diabetes clinic visit, patients with type 2 diabetes underwent a physical examination, detailed medical history, laboratory measurement of HbA1c, and completed two questionnaires (Pediatric Quality of Life Inventory and Children’s Depression Inventory) to assess their overall quality of life and the presence of depressive symptoms. Patients were then randomized to the intervention (the buddy system) or conventional treatment (standard care). All patients were scheduled to return for follow-up at 3- and 6-mo after their initial visit. HbA1c was determined at all visits (*i.e*., at screening and at the 3- and 6-mo follow-up visits) and quality of life and depressive symptoms were evaluated at the screening visit and were reassessed at the 6-mo visit.

**RESULTS:** Ten adolescents, recruited from a pool of approximately 200 adolescents, enrolled over a two-year time period, leading to premature termination of the study. In contrast, we easily recruited motivated lay volunteers. We found no change in HbA1c from the initial to the 6-mo visit in either group, yet our small sample size limited systematic assessment of this outcome. Participants repeatedly missed clinic appointments, failed to conduct self-glucose-monitoring and rarely brought their glucometers to clinic visits. Total quality of life scores (72.6 ± 6.06) at screening were similar to previously reported scores in adolescents with type 2 diabetes (75.7 ± 15.0) and lower than scores reported in normal-weight (81.2 ± 0.9), overweight (83.5 ± 1.8), and obese youths without diabetes (78.5 ± 1.8) or in adolescents with type 1 diabetes (80.5 ± 13.1). Among adolescents who returned for their 6-month visit, there were no differences in total quality of life scores (70.2 ± 9.18) between screening and follow-up.

**CONCLUSION:** Our approach, effective in adults with type 2 diabetes, was unsuccessful among adolescents and emphasizes the need for innovative strategies for diabetes treatment in adolescent patients.

**Key words:** Diabetes mellitus type 2; Adolescent; Hemoglobin A1c; Quality of life; Social support

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Our manuscript details results and challenges during a simple psychosocial intervention trial where young, healthy and motivated lay volunteer partners (“buddies”) were assigned to adolescents with type 2 diabetes. We experienced difficulty in the recruitment and retention of adolescent patients, which ultimately led to premature study termination. Despite our negative findings, our manuscript calls attention to the fact that psychosocial approaches shown to be effective in adults with type 2 diabetes may not translate in adolescent patients and conveys a unique and important message to other investigators who may wish to attempt similar interventions among adolescents with type 2 diabetes.

Sylvetsky AC, Nandagopal R, Nguyen T, Abegg M, Nagarur M, Kaplowitz P, Rother KI. Buddy Study: Partners for better health in adolescents with type 2 diabetes. *World J Diabetes* 2015; In press

**Introduction**

Type 2 diabetes in adolescence is generally associated with obesity, a positive family history of type 2 diabetes, and a low-income minority background[[1](#_ENREF_1),[2](#_ENREF_2)]. Beta cell failure in adolescents progresses more rapidly than in adults and responds less to medical treatment as was shown in the recently completed TODAY trial (Treatment Options for Type 2 Diabetes in Adolescents and Youth)[[3](#_ENREF_3)]. Because the progression of diabetes in obese adolescents occurs more rapidly than in adults and in youth with type 1 diabetes[[2](#_ENREF_2)], early intervention is critical in this patient population. This trial is the only existing large-scale intervention study in youth with type 2 diabetes, which is in part due to difficult recruitment of these individuals[[4](#_ENREF_4)]. Obesity related co-morbidities together with potentially long-lasting diabetes, dramatically increases the risk of macrovascular disease later in life. Microvascular complications including peripheral neuropathy and retinopathy have also been shown to occur, even at such a young age[[5](#_ENREF_5),[6](#_ENREF_6)].

Guidelines from the American Academy of Pediatrics recommend that clinicians combine weight management counseling focused on improving diet, increasing physical activity, and reducing television and computer screen time along with metformin administration at the time of diabetes diagnosis[[1](#_ENREF_1)]. It is well known, however, that adolescent patients[[7](#_ENREF_7),[8](#_ENREF_8)] and those from low-income minority groups[[8](#_ENREF_8)] often have difficulties in adhering to these recommended life-style changes and medical treatments. Even among adults who historically exhibit better compliance compared to adolescents, non-adherence is one of the most important barriers to successful treatment[[9](#_ENREF_9)]. Psychosocial interventions in adults with type 2 diabetes have shown promise in increasing adherence to treatment[[10-15](#_ENREF_10)] and/or improving hemoglobin A1c (HbA1c)[[16-22](#_ENREF_16)]. For example, two interventions[[16](#_ENREF_16),[17](#_ENREF_17)], in which adults with type 2 diabetes were paired with age- and gender- matched lay peer mentors (who also had diabetes), were effective in improving blood glucose control. Other interventions involving diabetes self-management education conducted in a group setting[[18-21](#_ENREF_18)] have also led to better glycemia, while diabetes support delivered *via* online[[23](#_ENREF_23)], telephone[[10](#_ENREF_10),[14](#_ENREF_14),[22](#_ENREF_22)], or text messaging[[15](#_ENREF_15)] programs has improved treatment adherence. Educational and psychosocial interventions have also been effective in improving both HbA1c and psychological health in adolescents with type 1 diabetes[[24](#_ENREF_24)], yet to our knowledge, similar studies have not been conducted in adolescents with type 2 diabetes. The objectives of this study were to test whether a low-cost intervention in which a young, healthy and motivated lay volunteer partner is assigned to an adolescent with type 2 diabetes, can improve HbA1c, adherence to treatment, and quality of life.

**MATERIALS AND METHODS**

***Participants***

Adolescents (aged 12-20 years) with type 2 diabetes received information about the “Buddy Study” from their pediatric endocrinologists during routine outpatient diabetes clinic visits at Children’s National Medical Center (CNMC) in Washington, DC and at the National Institutes of Health Clinical Center (NIH CC) in Bethesda, MD. Whenever possible, interested patients and their caregivers also met with a trained research assistant to learn more about the study immediately after their clinic appointment. Recruitment occurred between January 2010 and November 2011. The diagnosis of type 2 diabetes was based on their primary physician’s assessment[[25](#_ENREF_25)]. For study inclusion, patients had to have a documented HbA1c ≥ 7% (≥ 53 mmol/mol). Individuals were excluded if they had a significant comorbidity or psychological disorder that would interfere with their ability to participate (*e.g*., a history of violent behavior, which could pose a risk to the lay volunteers), or if they were pregnant or planning to become pregnant within six months of the initial visit. Informed written consent and assent (in individuals < 18 years of age) were obtained prior to enrollment. The study protocol, consents and all study procedures were approved by the Institutional Review Boards at the CNMC and the NIH CC and were in accordance with the Declaration of Helsinki.

Lay volunteers, or “buddies,” between 18 and 25 years of age were recruited from a pool of research assistants at the National Institutes of Health (NIH). Volunteers were screened and selected by the study physicians and were matched by gender with an adolescent patient. This was deemed necessary to facilitate the home visits. Further matching was not conducted (*e.g.*, by race, ethnicity, body mass index or education) for practical reasons due to the known demographic characteristics of the NIH research assistants. The lay volunteers did not have type 2 diabetes. All volunteers underwent standardized training and criminal background check in collaboration with the NIH Volunteer Services office and received specific training about the management of home visits from a NIH social worker.

***Study design***

The “Buddy Study” was a randomized, parallel-group study of six months duration conducted at Children’s National Medical Center (CNMC) in Washington, DC and the National Institutes of Health Clinical Center (NIH CC) in Bethesda, MD. The NIH CC depends on physician-referred or self-referred research participants while CNMC is a tertiary medical center in which approximately 400 visits of youths with type 2 diabetes (new and established disease) take place annually. During the initial screening visit, which coincided with a routine outpatient diabetes clinic visit, patients with type 2 diabetes underwent a physical examination, detailed medical history, laboratory measurement of HbA1c, and completed two questionnaires (Pediatric Quality of Life Inventory (PedsQL)[[26](#_ENREF_26)] and Children’s Depression Inventory (CDI)[[27](#_ENREF_27)] to assess their overall quality of life and the presence of depressive symptoms. Patients were then randomized to the intervention (the buddy system) or conventional treatment (standard care). All patients were scheduled to return for follow-up at 3- and 6-mo after their initial visit. Participants received modest financial compensation for their time and inconvenience ($100).

The intervention arm (buddy group) was designed to receive weekly telephone calls from their assigned buddies and one home visit per month (lasting 30-60 min) to encourage “bonding” in a comfortable environment. Meetings between patients and buddies took place at locations of the patient’s choice (preferably at their home), and contacts were made *via* phone, cell phone, and e-mail. Alternative buddy-patient meeting places included schools, coffee-shops, or libraries chosen by both parties at a mutually convenient time if home visits were declined by the participant or his/her family. Buddies were encouraged to not only ask the patient about diabetes management and provide telephone reminders for diabetes follow-up appointments, but also to discuss the patient’s home and social life in order to promote a nurturing and motivating relationship. Buddies were strictly prohibited from providing medical advice and were told to contact the Principal Investigator should a need for medical advice arise. Details of the study procedures are shown in Figure 1.

***Measures***

The primary outcome was the effect of the intervention on hemoglobin A1c (HbA1c), which was measured using the Siemens-Bayer DCA 2000+. At all visits, HbA1c, height and weight were measured, and body mass index (BMI) was calculated. Change in HbA1c for the intervention arm (buddy group) versus the conventional treatment group was compared using the Student’s *t*-test. Socio-demographic and clinically relevant information including self-reported race/ethnicity, family history of diabetes and patient medication use was also collected. All clinical information and laboratory data were compiled in the *eSphere* Clinical Trials Data Management System (Espirit Health, Chicago, IL).

Adolescents’ quality of life and depressive symptoms were evaluated at the screening visit and were reassessed at the 6-mo visit using the PedsQL[[26](#_ENREF_26)], a validated 23-item questionnaire to assess physical, emotional, social and school functioning and the CDI[[27](#_ENREF_27)], a validated 27-item self-report measure designed to determine the extent and severity of depressive symptoms in children (cut-off for depression score ≥ 13), respectively.

**RESULTS**

Forty adolescents with type 2 diabetes were screened and eligible. As shown in Figure 1, ten adolescents were enrolled in the “Buddy Study”, of whom five were randomized to the intervention arm and paired with a buddy. Five adolescents (three randomized to the buddy group and two to the conventional arm) returned to the clinic for both 3- and 6-mo follow-up visits. Baseline characteristics and a brief case description for each adolescent are shown in Table 1. The majority of our study participants were Non-Hispanic Black, obese (mean BMI 37.0 ± 13.7 kg/m2) and all but one had a positive family history for type 2 diabetes. The average age was 15.8 ± 2.0 years, diabetes duration 22.1 ± 20.4 mo, and the starting HbA1c was 10.6% ± 3.0% (92.4 mmol/mol) with all participants receiving metformin and four of ten receiving insulin. Diabetes and obesity related comorbidities were documented in 50%, but not all patients had undergone screening for retinopathy.

While early study termination prevented us from systematically assessing the primary outcome, HbA1c did not improve at 6 mo compared to screening in either group. Total quality of life scores (72.6 ± 6.06) at screening were similar to previously reported scores in adolescents with type 2 diabetes (75.7 ± 15.0)[[28](#_ENREF_28)] and lower than scores reported in normal-weight (81.2 ± 0.9), overweight (83.5 ± 1.8), and obese youths without diabetes (78.5 ± 1.8)[[29](#_ENREF_29)] or in adolescents with type 1 diabetes (80.5 ± 13.1)[[28](#_ENREF_28)]. Among adolescents who returned for their 6-month visit, there were no differences in total quality of life scores (70.2 ± 9.18) between screening and follow-up. Using the CDI criteria for depression, three adolescents were depressed but none was suicidal at screening. No participant received treatment with antidepressants.

The average age of our lay volunteers (buddies) was 23.0 ± 0.71 years and four of the five volunteers were female, as adolescent patients and buddies were gender matched. The four female buddies all self-identified as non-Hispanic White, while the one male buddy self-identified as Asian.

**DISCUSSION**

In this study, we aimed to test whether a “buddy” intervention in adolescent patients with type 2 diabetes was effective in improving HbA1c, adherence to treatment, and quality of life. This particular approach has been shown to be promising in adults with type 2 diabetes and similar educational and psychosocial interventions have been successful in adolescents with type 1 diabetes[[24](#_ENREF_24)], but has not been tested in adolescents[[10](#_ENREF_10),[11](#_ENREF_11)].

Recruitment of adolescents with type 2 diabetes was difficult. Only ten adolescents, recruited from a pool of approximately 200 outpatients at CNMC, enrolled over a two-year time period, which led to premature termination of the study. In contrast, we easily recruited motivated lay volunteers. We found no change in HbA1c from the initial to the 6-mo visit in either group, yet our small sample size limited systematic assessment of this outcome. The early termination of the “Buddy Study” was particularly disappointing, as the scientific community supported the “Buddy Study” as an important and worthwhile trial. One team member (RN) was awarded the 2010 Endocrine Fellows Foundation Marilyn Fishman Grant for Diabetes Research for designing the protocol. Furthermore, the study was promoted by the Scientific Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) as part of the “Healthy Moments” radio series[[30](#_ENREF_30)]. Our experience may serve to caution for other investigators in attempting to implement similar strategies for diabetes management among adolescents. It is possible that others have conducted but not reported such experience, because bias against submission and publication of negative study findings is problematic in the medical literature[[31](#_ENREF_31)]. Our seemingly “unexciting” findings convey a unique message for other investigators[[32](#_ENREF_32)].

Challenges in the recruitment of adolescents into clinical research protocols have been well described[[4](#_ENREF_4),[33](#_ENREF_33),[34](#_ENREF_34)]. Similar to most adolescents, these youths with type 2 diabetes strive to fit in with peer norms and wish to conform to their perception of what is “normal”, posing a barrier to participation in research studies[[35](#_ENREF_35)]. Even in the TODAY trial, the largest and most resource-intensive randomized-controlled intervention trial to be conducted in adolescents with type 2 diabetes[[36](#_ENREF_36)], recruitment was difficult and the projected recruitment period had to be extended by two years[[37](#_ENREF_37)]. This emphasizes the need for improved recruitment strategies specifically targeting adolescents.

As reflected in our cohort, data from both TODAY and the “Search for Diabetes in Youth” (SEARCH) trials[[37](#_ENREF_37),[38](#_ENREF_38)] have demonstrated that type 2 diabetes disproportionately affects youth from racial/ethnic minority groups. In addition to facing difficulties with recruitment of individuals from minority groups[[39](#_ENREF_39),[40](#_ENREF_40)] and younger age groups[[41](#_ENREF_41)] into chronic disease prevention and treatment programs, epidemiologic data suggest that poor blood glucose control is most prevalent among these subgroups[[38](#_ENREF_38)]. In accordance with the emerging field of molecular pathological epidemiology (MPE)[[42](#_ENREF_42)], complex diseases including type 2 diabetes may comprise various subtypes involving heterogeneous subpopulations. Because the etiology underlying type 2 diabetes is multifactorial, different disease subtypes may be associated with different biological, social, and environmental determinants and diverse natural histories. Thus, diabetes may progress at different rates and respond differently to interventions and treatments in certain individuals[[43](#_ENREF_43)], as we observed in our study of adolescents with type 2 diabetes.

We observed low self-reported quality of life and frequent depressive symptoms, both of which are associated with exacerbated metabolic disturbance and poor glycemia control[[44](#_ENREF_44)]. Given the high rates of treatment failure on metformin among adolescents[[36](#_ENREF_36)], the implementation of a buddy system to encourage and sustain lifestyle changes and improve psychosocial health was a seemingly hopeful undertaking. However, even the best-designed programs cannot be effective if adolescents do not participate[[45](#_ENREF_45)] nor can they be successful if adolescents who do participate are not compliant with medications and study requirements. This is exemplified by the high frequency of missed clinic appointments, continued failure to conduct self-glucose monitoring, and widespread non-compliance with medication and lifestyle recommendations. Of note, the “Buddy Study” was designed to place the burden and inconvenience of study participation on the research team rather than on the study participants (*e.g*., meetings between patients and buddies took place at locations of the patient’s choice, and contacts were made via phone, cell phone, and e-mail).

Several modifications to our study may have facilitated improved enrollment and/or enhanced compliance with treatment recommendations. First, pairing adolescents with peer volunteers who themselves have type 2 diabetes[[16](#_ENREF_16)] and had successfully improved their glycemia[[46](#_ENREF_46)] or with lay volunteers of the same race/ethnicity and/or socio-economic status[[46](#_ENREF_46)] may have been more effective in building trust between adolescents and their buddies[[47](#_ENREF_47)] and generating interest in study participation. Approaching adolescents at the time of their diabetes diagnosis may also have been helpful, as early intervention has shown promise in chronic disease management[[48](#_ENREF_48)]. Future efforts to raise adolescent understanding of the physiology of type 2 diabetes may also be worthwhile in enhancing participation[[49](#_ENREF_49)].

Another hurdle is the limited time a practicing physician can afford to spend on clinical trial recruitment. In our study, several patients were not informed about the study by the treating physician because the medical, psychological and/or psychosocial situation was so complicated that no further topics could be discussed in the short time of the clinic visit. Though we attempted to have a research assistant present at all times, logistically this was not feasible.

In summary, our study provides insight into the difficulties of translating an intervention effective in adults with type 2 diabetes into a successful approach in adolescents with the same condition. The challenges faced during the “Buddy Study” may serve as a caution to other investigators attempting to implement similar strategies for diabetes management among adolescents. Our findings emphasize the urgent need for improved recruitment strategies specifically targeting adolescents.

**ACKNOWLEDGEMENTS**

We would like to thank Tammy Nguyen and Rebecca Brown for their assistance in the design of this study, Fran E Cogen, MD, for meeting with participants at follow-up visits, and Ann Sloan, LCSW-C, for her training of volunteers and Courtney Duncan, LICSW, and her staff at NIH Volunteer Services. We would also like to especially thank all of the volunteers who agreed to serve as buddies throughout the study.

**Comments**

***Background***

Type 2 diabetes in adolescence is generally associated with obesity, a positive family history of type 2 diabetes, and a low-income minority background. Obesity related co-morbidities together with potentially long-lasting diabetes, dramatically increases the risk micro-vascular complications at a young age and of macro-vascular complications later in life.

***Research frontiers***

Psychosocial interventions in adults with type 2 diabetes and in youth with type 1 diabetes have shown promise in increasing adherence to treatment, improving psychological health in adolescents with type 1 diabetes, and/or lowering hemoglobin A1c (HbA1c), yet similar studies have not been conducted in adolescents with type 2 diabetes.

***Innovations and breakthroughs***

The study tested an intervention shown to be effective in adults with type 2 diabetes in a cohort of adolescents with the same condition. The findings provide insight into the difficulties of translating an intervention effective in adults with type 2 diabetes into a successful approach in adolescents and highlight the need for innovative strategies to improve recruitment and retention of adolescents with type 2 diabetes into diabetes treatment programs.

***Applications***

Given the recruitment challenges faced, our study may serve as a caution to other investigators attempting to implement similar strategies for diabetes management among adolescents. Based on our experience, additional practical considerations for designing interventions in adolescents may include pairing adolescents with peer volunteers who themselves have type 2 diabetes and had successfully improved their glycemia or with lay volunteers of the same race/ethnicity and/or socio-economic status. In addition, future efforts to raise adolescent understanding of the physiology of type 2 diabetes may also be worthwhile in motivating adolescents to participate in diabetes treatment programs.

***Terminology***

While we expect that the terminology in our manuscript is familiar to most readers, we wish to define two critical terms mentioned repeatedly in the manuscript: psychosocial intervention and (HbA1c). Psychosocial interventions are interventions that are designed to change behavior and have a direct focus on a person’s social environment including interpersonal interactions and social support. This is in contrast to a medical approach, in which participants are prescribed medication or assigned to a specific diet. (HbA1c) is a commonly used indicator of glycemic control over a 3-4 mo period. (HbA1c) measures the percentage of one’s hemoglobin (a protein in red blood cells) that is glycosylated or in other words, has sugar attached to it.

***Peer-review***

The study is an interesting analysis about the insight into the difficulties of translating an intervention effective in adults with type 2 diabetes into a successful approach in adolescents with the same disease.

**REFERENCES**

1 **Copeland KC**, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, Springer SC, Thaker VV, Anderson M, Spann SJ, Flinn SK. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. *Pediatrics* 2013; **131**: 364-382 [PMID: 23359574 DOI: 10.1542/peds.2012-3494]

2 **D'Adamo E**, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. *Diabetes Care* 2011; **34** Suppl 2: S161-S165 [PMID: 21525449 DOI: 10.2337/dc11-s212]

3 **Zeitler P**, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med* 2012; **366**: 2247-2256 [PMID: 22540912 DOI: 10.1056/NEJMoa1109333]

4 **Nguyen TT**, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI. Challenging recruitment of youth with type 2 diabetes into clinical trials. *J Adolesc Health* 2014; **54**: 247-254 [PMID: 24161585 DOI: 10.1016/j.jadohealth.2013.08.017]

5 **Jaiswal M**, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Rodriguez BL, Pop-Busui R, Feldman EL. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. *Diabetes Care* 2013; **36**: 3903-3908 [PMID: 24144652 DOI: 10.2337/dc13-1213]

6 **Today Study Group**. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. *Diabetes Care* 2013; **36**: 1772-1774 [PMID: 23704677 DOI: 10.2337/dc12-2387]

7 **Barnes NS**, White PC, Hutchison MR. Time to failure of oral therapy in children with type 2 diabetes: a single center retrospective chart review. *Pediatr Diabetes* 2012; **13**: 578-582 [PMID: 22646303 DOI: 10.1111/j.1399-5448.2012.00873.x]

8 **DiMatteo MR**. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. *Med Care* 2004; **42**: 200-209 [PMID: 15076819]

9 **Kirkman MS**, Herrera V, Hawk G, Fonseca V, Schmidttdiel JA, Herman WH, Aubert RE. Determinants of Non-Adherence to Diabetes Medications {abstract}. In ADA Scientific Sessions, Chicago, IL, June 21-25, 2013

10 **Lorig K**, Ritter PL, Villa FJ, Armas J. Community-based peer-led diabetes self-management: a randomized trial. *Diabetes Educ* 2009; **35**: 641-651 [PMID: 19407333 DOI: 10.1177/0145721709335006]

11 **Keyserling TC**, Samuel-Hodge CD, Ammerman AS, Ainsworth BE, Henríquez-Roldán CF, Elasy TA, Skelly AH, Johnston LF, Bangdiwala SI. A randomized trial of an intervention to improve self-care behaviors of African-American women with type 2 diabetes: impact on physical activity. *Diabetes Care* 2002; **25**: 1576-1583 [PMID: 12196430]

12 **Allen NA**, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. *Diabetes Res Clin Pract* 2008; **80**: 371-379 [PMID: 18304674 DOI: 10.1016/j.diabres.2008.01.006]

13 **Babamoto KS**, Sey KA, Camilleri AJ, Karlan VJ, Catalasan J, Morisky DE. Improving diabetes care and health measures among hispanics using community health workers: results from a randomized controlled trial. *Health Educ Behav* 2009; **36**: 113-126 [PMID: 19188371 DOI: 10.1177/1090198108325911]

14 **Rotheram-Borus MJ**, Tomlinson M, Gwegwe M, Comulada WS, Kaufman N, Keim M. Diabetes buddies: peer support through a mobile phone buddy system. *Diabetes Educ* 2012; **38**: 357-365 [PMID: 22546740 DOI: 10.1177/0145721712444617]

15 **Vervloet M**, van Dijk L, Santen-Reestman J, van Vlijmen B, van Wingerden P, Bouvy ML, de Bakker DH. SMS reminders improve adherence to oral medication in type 2 diabetes patients who are real time electronically monitored. *Int J Med Inform* 2012; **81**: 594-604 [PMID: 22652012 DOI: 10.1016/j.ijmedinf.2012.05.005]

16 **Heisler M**, Vijan S, Makki F, Piette JD. Diabetes control with reciprocal peer support versus nurse care management: a randomized trial. *Ann Intern Med* 2010; **153**: 507-515 [PMID: 20956707 DOI: 10.7326/0003-4819-153-8-201010190-00007]

17 **Long JA**. ''Buddy system'' of peer mentors may help control diabetes. *LDI Issue Brief* 2012; **17**: 1-4 [PMID: 22451999]

18 **Thom DH**, Ghorob A, Hessler D, De Vore D, Chen E, Bodenheimer TA. Impact of peer health coaching on glycemic control in low-income patients with diabetes: a randomized controlled trial. *Ann Fam Med* 2013; **11**: 137-144 [PMID: 23508600 DOI: 10.1370/afm.1443]

19 **Rosal MC**, Olendzki B, Reed GW, Gumieniak O, Scavron J, Ockene I. Diabetes self-management among low-income Spanish-speaking patients: a pilot study. *Ann Behav Med* 2005; **29**: 225-235 [PMID: 15946117]

20 **Deakin TA**, Cade JE, Williams R, Greenwood DC. Structured patient education: the diabetes X-PERT Programme makes a difference. *Diabet Med* 2006; **23**: 944-954 [PMID: 16922700 DOI: 10.1111/j.1464-5491.2006.01906.x]

21 **Kulzer B**, Hermanns N, Reinecker H, Haak T. Effects of self-management training in Type 2 diabetes: a randomized, prospective trial. *Diabet Med* 2007; **24**: 415-423 [PMID: 17298590 DOI: 10.1111/j.1464-5491.2007.02089.x]

22 **Walker EA**, Schecter CB, Gonzalez JS, Silver LD. Results of the Bronx A1c Telephonic Behavioral Intervention Study In American Diabetes Association Annual Meeting. Chicago, IL, 2013

23 **Lorig K**, Ritter PL, Laurent DD, Plant K, Green M, Jernigan VB, Case S. Online diabetes self-management program: a randomized study. *Diabetes Care* 2010; **33**: 1275-1281 [PMID: 20299481 DOI: 10.2337/dc09-2153.2875437]

24 **Hampson SE**, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, Kimber A, Shaw K, Walker J. Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. *Health Technol Assess* 2001; **5**: 1-79 [PMID: 11319990]

25 **Search Study Group**. SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. *Control Clin Trials* 2004; **25**: 458-471 [PMID: 15465616 DOI: 10.1016/j.cct.2004.08.002]

26 **Varni JW**, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. *Med Care* 2001; **39**: 800-812 [PMID: 11468499]

27 **Kovacs M**. The Children’s Depression Inventory (CDI) technical manual. Toronto: ON: Multi-Health Systems, 2003

28 **Hilliard ME**, Lawrence JM, Modi AC, Anderson A, Crume T, Dolan LM, Merchant AT, Yi-Frazier JP, Hood KK. Identification of minimal clinically important difference scores of the PedsQL in children, adolescents, and young adults with type 1 and type 2 diabetes. *Diabetes Care* 2013; **36**: 1891-1897 [PMID: 23340884 DOI: 10.2337/dc12-1708.3687260]

29 **Gopinath B**, Baur LA, Burlutsky G, Mitchell P. Adiposity adversely influences quality of life among adolescents. *J Adolesc Health* 2013; **52**: 649-653 [PMID: 23425948 DOI: 10.1016/j.jadohealth.2012.11.010]

30 **NIDDK**. Is Everything Better with a Friend? In Healthy Moments. Bethesda, MD: National Institutes of Health, 2011

31 **Olson CM**, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, Zhu Q, Reiling J, Pace B. Publication bias in editorial decision making. *JAMA* 2002; **287**: 2825-2828 [PMID: 12038924]

32 **Connor JT**. Positive reasons for publishing negative findings. *Am J Gastroenterol* 2008; **103**: 2181-2183 [PMID: 18671812 DOI: 10.1111/j.1572-0241.2008.02028.x]

33 **Liese AD**, Liu L, Davis C, Standiford D, Waitzfelder B, Dabelea D, Bell R, Williams D, Imperatore G, Lawrence JM. Participation in pediatric epidemiologic research: the SEARCH for Diabetes in Youth Study experience. *Contemp Clin Trials* 2008; **29**: 829-836 [PMID: 18573350 DOI: 10.1016/j.cct.2008.05.008]

34 **Drews KL**, Harrell JS, Thompson D, Mazzuto SL, Ford EG, Carter M, Ford DA, Yin Z, Jessup AN, Roullet JB. Recruitment and retention strategies and methods in the HEALTHY study. *Int J Obes* (Lond) 2009; **33** Suppl 4: S21-S28 [PMID: 19623184 DOI: 10.1038/ijo.2009.113.2758033]

35 **Rhee H**, Ciurzynski SM, Yoos HL. Pearls and pitfalls of community-based group interventions for adolescents: lessons learned from an adolescent asthma cAMP study. *Issues Compr Pediatr Nurs* 2008; **31**: 122-135 [PMID: 18728958 DOI: 10.1080/01460860802272888.2565511]

36 **Zeitler P**, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. *Pediatr Diabetes* 2007; **8**: 74-87 [PMID: 17448130 DOI: 10.1111/j.1399-5448.2007.00237.x.2752327]

37 **Copeland KC**, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab* 2011; **96**: 159-167 [PMID: 20962021 DOI: 10.1210/jc.2010-1642]

38 **Petitti DB**, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder B, Mayer-Davis E. Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. *J Pediatr* 2009; **155**: 668-672.e1-3 [PMID: 19643434 DOI: 10.1016/j.jpeds.2009.05.025]

39 **Brawner BM**, Volpe EM, Stewart JM, Gomes MM. Attitudes and beliefs toward biobehavioural research participation: voices and concerns of urban adolescent females receiving outpatient mental health treatment. *Ann Hum Biol* 2013; **40**: 485-495 [PMID: 23822716 DOI: 10.3109/03014460.2013.806590]

40 **Braunstein JB**, Sherber NS, Schulman SP, Ding EL, Powe NR. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. *Medicine* (Baltimore) 2008; **87**: 1-9 [PMID: 18204365 DOI: 10.1097/MD.0b013e3181625d78]

41 **Koopmans B**, Nielen MM, Schellevis FG, Korevaar JC. Non-participation in population-based disease prevention programs in general practice. *BMC Public Health* 2012; **12**: 856 [PMID: 23046688 DOI: 10.1186/1471-2458-12-856.3490995]

42 **Nishi A**, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and molecular pathological epidemiology. *Am J Prev Med* 2015; **48**: 116-119 [PMID: 25528613 DOI: 10.1016/j.amepre.2014.09.031.4274745]

43 **Ogino S**, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. *Am J Epidemiol* 2012; **176**: 659-667 [PMID: 22935517 DOI: 10.1093/aje/kws226.3571252]

44 **Hood KK**, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels S, Rodriguez B, Dolan LM. Metabolic and inflammatory links to depression in youth with diabetes. *Diabetes Care* 2012; **35**: 2443-2446 [PMID: 23033243 DOI: 10.2337/dc11-2329.3507554]

45 **Griffin JA**, Gilliland SS, Perez G, Upson D, Carter JS. Challenges to participating in a lifestyle intervention program: the Native American Diabetes Project. *Diabetes Educ* 2000; **26**: 681-689 [PMID: 11140076]

46 **Long JA**, Jahnle EC, Richardson DM, Loewenstein G, Volpp KG. Peer mentoring and financial incentives to improve glucose control in African American veterans: a randomized trial. *Ann Intern Med* 2012; **156**: 416-424 [PMID: 22431674 DOI: 10.7326/0003-4819-156-6-201203200-00004.3475415]

47 **Cuffee YL**, Hargraves JL, Rosal M, Briesacher BA, Schoenthaler A, Person S, Hullett S, Allison J. Reported racial discrimination, trust in physicians, and medication adherence among inner-city African Americans with hypertension. *Am J Public Health* 2013; **103**: e55-e62 [PMID: 24028222 DOI: 10.2105/AJPH.2013.301554]

48 **O'Brien SH**, Holubkov R, Reis EC. Identification, evaluation, and management of obesity in an academic primary care center. *Pediatrics* 2004; **114**: e154-e159 [PMID: 15286251]

49 **Trauth JM**, Musa D, Siminoff L, Jewell IK, Ricci E. Public attitudes regarding willingness to participate in medical research studies. *J Health Soc Policy* 2000; **12**: 23-43 [PMID: 11184441 DOI: 10.1300/J045v12n02\_02]

**P-Reviewer:** Gómez-Sáez J, Ogino S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Socio-demographic characteristics and case descriptions of adolescents with type 2 diabetes mellitus in the Buddy Study**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID** | **Age**  **(yr)** | **Diabetes**  **duration**  **(mo)** | **Sex** | **Ethnicity/ race** | **Medications**  **(hypoglycemic agents)** | **BMI**  **(kg/m2)** | **T2DM**  **family history** | **Complications and**  **comorbidities** | **Case description** |
| 1 | 14 | 22 | Male | Non-Hispanic Black | Metformin, Insulin | 24.1 | Yes | None | Control group. Poor medication and dietary compliance. Frequently consumed sugar-sweetened beverages and sneaked food late at night. Mother attributed behavior to depression and stress from a recent custody battle. Significant behavioral issues in school |
| 2 | 19 | 42 | Female | Non-Hispanic White | Metformin | 39.5 | Yes | Pre-hypertension | Buddy group. Fairly compliant with oral medications but noncompliant with insulin administration or blood glucose monitoring. Improved dietary habits but not exercise |
| 3 | 18 | 48 | Male | Non-Hispanic Black | Metformin | 39.5 | Yes | Cataract | Control group. History of anorexia. Complicated relationship with food. Has developmental delay and is in special education classes at school. Motivated to change lifestyle. Poor compliance with medication and glucose monitoring |
| 4 | 14 | 11 | Female | Non-Hispanic Black | Metformin | 42.9 | Yes | Hypertension | Buddy group. Poor compliance with medication. Skipped breakfast and lunch. Snacked excessively after school and in the evening. Mother had limited ability to supervise because she was not often home. |
| 5 | 13 | 5 | Female | Non-Hispanic Black | Metformin | 71.5 | Yes | Microalbuminuria | Control group. First seen in clinic for obesity at age 6, then lost to follow-up for 7 years prior to entering study. Gained 109.4 kg during this period. Discontinued sodas and juices and signed up for an exercise class, however, was subsequently lost to follow-up. |
| 6 | 14 | 13 | Female | Hispanic | Metformin | 34.2 | Yes | None | Buddy group. Unmotivated to initiate behavior change and non-compliant with medication and blood glucose monitoring. Unresponsive to communication attempts by assigned buddy. Did not report any exercise. No attempt to alter dietary habits. Lost to follow-up |
| 7 | 16 | 3 | Male | Asian/Pacific Islander | Metformin | 32.7 | Yes | None | Control group. Very motivated and successful at lifestyle modification. Reverted to poor diet and exercise following family emergency. Medications subsequently re-initiated but compliance remained poor. |
| 8 | 17 | 60 | Female | Asian/Pacific Islander | Metformin, Insulin | 24.7 | Yes | None | Buddy group. Poor medication compliance. No exercise despite parental encouragement. Removed sugar-sweetened beverages from diet but struggled with portion control. Improved compliance with medication regimen following hospitalization |
| 9 | 17 | 11 | Male | Non-Hispanic Black | Metformin, Insulin | 34.3 | Yes | Microalbuminuria Hypertension | Buddy group. Compliant with medication but not glucose monitoring or diet. Mother encouraged portion control with little success. Patient had developmental delay but appeared to understand importance of lifestyle modification and was motivated. However, lost to follow-up |
| 10 | 16 | 6 | Male | Non-Hispanic Black | Metformin, Insulin | 26.8 | No | None | Control group. Poor compliance with medication and blood glucose monitoring.  Lost to follow-up |
| ***n* = 10** | 15.8 ± 2.0 | 22.1 ± 20.4 | 50% F | 60% Non-Hispanic Black | 100% metformin 40% insulin | 37.0 ± 13.7 | 90% yes | 50% yes |  |

BMI: Body mass index; T2DM: Type 2 diabetes mellitus.

**Figure 1 Forty adolescents with type 2 diabetes were screened and eligible for participation in the “Buddy Study”.** Ten adolescents were enrolled in the study, of whom five were randomized to the intervention arm and paired with a buddy. The remaining five adolescents were randomized to the standard care group and were not paired with a buddy. Five adolescents (three randomized to the buddy group and two to the conventional arm) returned to the clinic for both 3- and 6-mo follow-up visits and six adolescents completed the six month study. HbA1C: Hemoglobin A1C.

**“Buddy” Group**

Weekly phone calls or messaging

1 home visit per month **(*n* = 5)**

**Conventional Arm**

Standard care for T2DM

**(*n* = 5)**

Declined participation; **(*n* = 30)**

**Screening:**

Patients with type 2 diabetes,

Age 12-20y and HbA1c ≥ 7%

(53 mmol/mol)

**(*n* = 40)**

**Consent** and

**Randomization** **(*n* = 10)**

6 month visit in diabetes clinic: HbA1c, meter downloads **(*n* = 3)**

***n* = 1 lost to follow-up**

***n* = 1 lost to follow-up**

Study design, enrollment and procedures

3-mo visit in diabetes clinic: HbA1c, meter downloads **(*n* = 3)**

6 mo visit in diabetes clinic: HbA1c, meter downloads **(*n* = 3)**

3- month visit in diabetes clinic: HbA1c, meter downloads **(*n* = 4)**

***n* = 1 returned for final visit**

***n* = 1 did not attend**

***n* = 1 lost to follow-up**

***n* = 1 lost to follow-up**